{
    "root": "ae134e70-c01c-4b1d-81c0-7fcfd1193c36",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Lurasidone Hydrochloride",
    "value": "20250224",
    "ingredients": [
        {
            "name": "LURASIDONE HYDROCHLORIDE",
            "code": "O0P4I5851I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_70732"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        }
    ],
    "indications": {
        "text": "lurasidone hydrochloride tablet indicated : treatment adult adolescent patients ( 13 17 years ) schizophrenia [ ( 14.1 ) ] . monotherapy treatment adult pediatric patients ( 10 17 years ) major depressive episode associated bipolar disorder ( bipolar depression ) [ ( 14.2 ) ] . adjunctive treatment lithium valproate adult patients major depressive episode associated bipolar disorder ( bipolar depression ) [ ( 14.2 ) ] .",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "bipolar disorder (DOID:3312)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3312"
            },
            {
                "text": "depression (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "lurasidone hydrochloride tablets taken food ( least 350 calories ) . food substantially increases absorption lurasidone ( 2.3 , 12.3 ) . indication starting dose recommended dose schizophrenia \u2013 adults ( 2.1 ) 40 mg per day 40 mg 160 mg per day schizophrenia adolescents ( 13 17 years ) ( 2.1 ) 40 mg per day 40 mg 80 mg per day bipolar depression adults ( 2.2 ) 20 mg per day 20 mg 120 mg per day bipolar depression pediatric patients ( 10 17 years ) ( 2.2 ) 20 mg per day 20 mg 80 mg per day moderate severe renal impairment : recommended starting dose 20 mg per day , maximum recommended dose 80 mg per day ( 2.4 , 8.6 ) . moderate severe hepatic impairment : recommended starting dose 20 mg per day . maximum recommended dose 80 mg per day moderate hepatic impairment 40 mg per day severe hepatic impairment ( 2.5 , 8.7 ) . concomitant moderate cyp3a4 inhibitor ( e.g . , diltiazem ) : lurasidone hydrochloride tablets dose reduced half original dose level . recommended starting dose 20 mg per day . maximum recommended dose 80 mg per day ( 2.6 , 7.1 ) . concomitant moderate cyp3a4 inducer : may necessary increase dose lurasidone hydrochloride tablets ( 2.6 , 7.1 ) .",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "bipolar depression (DOID:3312)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3312"
            },
            {
                "text": "depression (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe hepatic impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            },
            {
                "disease": "severe renal impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "lurasidone hydrochloride tablets 20 mg available white off-white , round shaped film coated tablet , debossed \u201c 335 \u201d one side plain reverse side . supplied follows : bottles 30 : ndc 23155-887-03 bottles 90 : ndc 23155-887-09bottles 500 : ndc 23155-887-05bulk pack : ndc 23155-887-18 lurasidone hydrochloride tablets 40 mg available white off-white , round shaped film coated tablet , debossed \u201c 336 \u201d one side plain reverse side . supplied follows : bottles 30 : ndc 23155-888-03 bottles 90 : ndc 23155-888-09bottles 500 : ndc 23155-888-05bulk pack : ndc 23155-888-18 lurasidone hydrochloride tablets 60 mg available white off-white , capsule shaped film coated tablet , debossed \u201c 337 \u201d one side plain reverse side . supplied follows : bottles 30 : ndc 23155-889-03 bottles 90 : ndc 23155-889-09bottles 500 : ndc 23155-889-05bulk pack : ndc 23155-889-18 lurasidone hydrochloride tablets 80 mg available white off-white , oval shaped film coated tablet , debossed \u201c 338 \u201d one side plain reverse side . supplied follows : bottles 30 : ndc 23155-890-03 bottles 90 : ndc 23155-890-09bottles 500 : ndc 23155-890-05bulk pack : ndc 23155-890-18 lurasidone hydrochloride tablets 120 mg available white off-white , oval shaped film coated tablet , debossed \u201c 339 \u201d one side plain reverse side . supplied follows : bottles 30 : ndc 23155-891-03bottles 100 : ndc 23155-891-01bottles 500 : ndc 23155-891-05bottles 1000 : ndc 23155-891-10bulk pack : ndc 23155-891-18 storage store lurasidone hydrochloride tablets 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "known hypersensitivity lurasidone hcl components formulation . angioedema observed lurasidone [ ( 6.1 ) ] . strong cyp3a4 inhibitors ( e.g . , ketoconazole , clarithromycin , ritonavir , voriconazole , mibefradil , etc . ) [ ( 7.1 ) ] . strong cyp3a4 inducers ( e.g . , rifampin , avasimibe , st. john \u2019 wort , phenytoin , carbamazepine , etc . ) [ ( 7.1 ) ] .",
    "indications_original": "Lurasidone hydrochloride tablet is indicated for:\n                  \n                     Treatment of adult and adolescent patients (13 to 17 years) with schizophrenia [see Clinical Studies (14.1)].\n                     Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies (14.2)].\n                     Adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies (14.2)].",
    "contraindications_original": "Lurasidone hydrochloride tablets should be taken with food (at least 350 calories). Administration with food substantially increases the absorption of lurasidone ( 2.3 , 12.3 ). Indication Starting Dose Recommended Dose Schizophrenia \u2013 adults ( 2.1 ) 40 mg per day 40 mg to 160 mg per day Schizophrenia adolescents (13 to 17 years) ( 2.1 ) 40 mg per day 40 mg to 80 mg per day Bipolar Depression adults ( 2.2 ) 20 mg per day 20 mg to 120 mg per day Bipolar Depression pediatric patients (10 to 17 years) ( 2.2 ) 20 mg per day 20 mg to 80 mg per day Moderate and Severe Renal Impairment: Recommended starting dose is 20 mg per day, and the maximum recommended dose is 80 mg per day ( 2.4 , 8.6 ). Moderate and Severe Hepatic Impairment: Recommended starting dose is 20 mg per day. The maximum recommended dose is 80 mg per day in moderate hepatic impairment and 40 mg per day in severe hepatic impairment ( 2.5 , 8.7 ). Concomitant Use of a Moderate CYP3A4 inhibitor (e.g., diltiazem): Lurasidone hydrochloride tablets dose should be reduced to half of the original dose level. Recommended starting dose is 20 mg per day. Maximum recommended dose is 80 mg per day ( 2.6 , 7.1 ). Concomitant Use of a Moderate CYP3A4 Inducer: It may be necessary to increase the dose of lurasidone hydrochloride tablets ( 2.6 , 7.1 ).",
    "warningsAndPrecautions_original": "Lurasidone Hydrochloride Tablets 20 mg are available as white to off-white, round shaped film coated tablet, debossed \u201c335\u201d on one side and plain on the reverse side. They are supplied as follows:\n                  Bottles of 30: NDC 23155-887-03\n                  Bottles of 90: NDC 23155-887-09Bottles of 500: NDC 23155-887-05Bulk Pack: NDC 23155-887-18\n                  Lurasidone Hydrochloride Tablets 40 mg are available as white to off-white, round shaped film coated tablet, debossed \u201c336\u201d on one side and plain on the reverse side. They are supplied as follows:\n                  Bottles of 30: NDC 23155-888-03\n                  Bottles of 90: NDC 23155-888-09Bottles of 500: NDC 23155-888-05Bulk Pack: NDC 23155-888-18\n                  Lurasidone Hydrochloride Tablets 60 mg are available as white to off-white, capsule shaped film coated tablet, debossed \u201c337\u201d on one side and plain on reverse side. They are supplied as follows:\n                  Bottles of 30: NDC 23155-889-03\n                  Bottles of 90: NDC 23155-889-09Bottles of 500: NDC 23155-889-05Bulk Pack: NDC 23155-889-18\n                  Lurasidone Hydrochloride Tablets 80 mg are available as white to off-white, oval shaped film coated tablet, debossed \u201c338\u201d on one side and plain on the reverse side. They are supplied as follows:\n                  Bottles of 30: NDC 23155-890-03\n                  Bottles of 90: NDC 23155-890-09Bottles of 500: NDC 23155-890-05Bulk Pack: NDC 23155-890-18\n                  Lurasidone Hydrochloride Tablets 120 mg are available as white to off-white, oval shaped film coated tablet, debossed \u201c339\u201d on one side and plain on reverse side. They are supplied as follows:\n                  Bottles of 30: NDC 23155-891-03Bottles of 100: NDC 23155-891-01Bottles of 500: NDC 23155-891-05Bottles of 1000: NDC 23155-891-10Bulk pack: NDC 23155-891-18\n                  \n                     \n                        Storage\n                     \n                  \n                  Store lurasidone hydrochloride tablets at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F) [See USP Controlled Room Temperature].",
    "adverseReactions_original": "Known hypersensitivity to lurasidone HCl or any components in the formulation. Angioedema has been observed with lurasidone [see Adverse Reactions (6.1)].\n                     Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) [see Drug Interactions (7.1)].\n                     Strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John\u2019s wort, phenytoin, carbamazepine, etc.) [see Drug Interactions (7.1)].",
    "drug": [
        {
            "name": "Lurasidone Hydrochloride",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_70732"
        }
    ]
}